دورية أكاديمية
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.
| العنوان: | Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. |
|---|---|
| المؤلفون: | Wang A; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Xu Y; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Yu Y; Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USA., Nead KT; Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USA., Kim T; Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USA., Xu K; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Dadaev T; The Institute of Cancer Research, London, SM2 5NG, UK., Saunders E; The Institute of Cancer Research, London, SM2 5NG, UK., Sheng X; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Wan P; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Pooler L; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Xia LY; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Chanock S; National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Berndt SI; National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Gapstur SM; American Cancer Society, Atlanta, GA 30303, USA., Stevens V; American Cancer Society, Atlanta, GA 30303, USA., Albanes D; National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Weinstein SJ; National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Gnanapragasam V; Division of Urology, Department of Surgery, University of Cambridge, Cambridge, CB2 0QQ, UK., Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria 3168, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria 3010, Australia., Nguyen-Dumont T; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria 3168, Australia.; Department of Clinical Pathology, The University of Melbourne, Victoria 3010, Australia., Milne RL; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria 3168, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria 3010, Australia., Pomerantz MM; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schmidt JA; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus N, DK-8200, Denmark., Stopsack KH; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Mucci LA; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Catalona WJ; Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Hetrick KN; Department of Genetic Medicine, Center for Inherited Disease Research, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA., Doheny KF; Department of Genetic Medicine, Center for Inherited Disease Research, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA., MacInnis RJ; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria 3010, Australia., Southey MC; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria 3168, Australia.; Department of Clinical Pathology, The University of Melbourne, Victoria 3010, Australia., Eeles RA; National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.; The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK., Wiklund F; Karolinska Institute, Solna 171 77, Sweden., Kote-Jarai Z; The Institute of Cancer Research, London, SM2 5NG, UK., de Smith AJ; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Conti DV; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Huff C; Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230, USA., Haiman CA; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA., Darst BF; Department of Population and Public Health Sciences, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. |
| المصدر: | Human molecular genetics [Hum Mol Genet] 2023 Jan 13; Vol. 32 (3), pp. 489-495. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: IRL Press at Oxford University Press Country of Publication: England NLM ID: 9208958 Publication Model: Print Cited Medium: Internet ISSN: 1460-2083 (Electronic) Linking ISSN: 09646906 NLM ISO Abbreviation: Hum Mol Genet Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, England ; New York : IRL Press at Oxford University Press, c1992- |
| مواضيع طبية MeSH: | Clonal Hematopoiesis* , Prostatic Neoplasms*/genetics, Male ; Humans ; Hematopoiesis/genetics ; Risk Factors ; Hematopoietic Stem Cells ; Mutation |
| مستخلص: | Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate cancer, the fifth leading cause of cancer death of men worldwide. We evaluated the association of age-related CHIP with overall and aggressive prostate cancer risk in two large whole-exome sequencing studies of 75 047 European ancestry men, including 7663 prostate cancer cases, 2770 of which had aggressive disease, and 3266 men carrying CHIP variants. We found that CHIP, defined by over 50 CHIP genes individually and in aggregate, was not significantly associated with overall (aggregate HR = 0.93, 95% CI = 0.76-1.13, P = 0.46) or aggressive (aggregate OR = 1.14, 95% CI = 0.92-1.41, P = 0.22) prostate cancer risk. CHIP was weakly associated with genetic risk of overall prostate cancer, measured using a polygenic risk score (OR = 1.05 per unit increase, 95% CI = 1.01-1.10, P = 0.01). CHIP was not significantly associated with carrying pathogenic/likely pathogenic/deleterious variants in DNA repair genes, which have previously been found to be associated with aggressive prostate cancer. While findings from this study suggest that CHIP is likely not a risk factor for prostate cancer, it will be important to investigate other types of CH in association with prostate cancer risk. (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.) |
| References: | Eur Urol. 2019 Sep;76(3):329-337. (PMID: 30777372) Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Nat Genet. 2021 Jan;53(1):65-75. (PMID: 33398198) Nature. 2019 Nov;575(7784):652-657. (PMID: 31748747) JCO Precis Oncol. 2020;4:32-43. (PMID: 32832836) Nature. 2020 Aug;584(7819):136-141. (PMID: 32581363) Nat Commun. 2020 Feb 14;11(1):886. (PMID: 32060290) N Engl J Med. 2017 Jul 13;377(2):111-121. (PMID: 28636844) Eur Urol. 2021 Aug;80(2):134-138. (PMID: 33941403) Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943) N Engl J Med. 2014 Dec 25;371(26):2477-87. (PMID: 25426838) Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. (PMID: 28803919) Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795) J Natl Cancer Inst. 2015 Nov 19;108(2):. (PMID: 26586665) Nature. 2020 Aug;584(7819):130-135. (PMID: 32581364) Nature. 2020 May;581(7809):434-443. (PMID: 32461654) Nat Commun. 2018 Oct 4;9(1):4079. (PMID: 30287866) Nat Rev Genet. 2021 Sep;22(9):603-617. (PMID: 33986496) Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6. (PMID: 14681465) Nat Genet. 2018 May;50(5):682-692. (PMID: 29662167) Eur Urol Oncol. 2020 Apr;3(2):224-230. (PMID: 31948886) Genome Res. 2002 Jun;12(6):996-1006. (PMID: 12045153) Nat Genet. 2014 Jun;46(6):624-8. (PMID: 24777449) Nat Genet. 2021 Jul;53(7):942-948. (PMID: 34183854) Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944) Nat Genet. 2012 May 06;44(6):651-8. (PMID: 22561519) Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5. (PMID: 24234437) N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837) Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1456-1463. (PMID: 27486019) Nature. 2020 Oct;586(7831):749-756. (PMID: 33087929) Nat Commun. 2017 Nov 9;8(1):1377. (PMID: 29123093) Nat Med. 2018 Jul;24(7):1015-1023. (PMID: 29988143) Nature. 2020 Oct;586(7831):763-768. (PMID: 33057201) N Engl J Med. 2016 Aug 4;375(5):443-53. (PMID: 27433846) J Natl Cancer Inst. 2021 May 4;113(5):616-625. (PMID: 32853339) |
| معلومات مُعتمدة: | 29017 United Kingdom CRUK_ Cancer Research UK; R01 CA196931 United States CA NCI NIH HHS; R00 CA246063 United States CA NCI NIH HHS; HHSN268201200008I United States HL NHLBI NIH HHS; K99 CA246063 United States CA NCI NIH HHS; 15007 United Kingdom CRUK_ Cancer Research UK; U01 CA164973 United States CA NCI NIH HHS; K08 CA263313 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20220826 Date Completed: 20230123 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC9851740 |
| DOI: | 10.1093/hmg/ddac214 |
| PMID: | 36018819 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2083 |
|---|---|
| DOI: | 10.1093/hmg/ddac214 |